Interleukin-36 gamma; Interleukin 1 family, member 9; Il1f9
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 10ng/ml, corresponding to a specific activity of >1.0×105IU/mg.
Lyophilized from a 0.2μm filtered solution in 1M MOPS, 10mM NaAC, pH7.6, with 2mM EDTA, 5% Trehalose, 0.02% Tween-20.
Endotoxin
Less than 0.1EU/μg of rMuIL-36γ, 152a.a. as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36γ is secreted when transfected into 293-T cells and it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). Furthermore, IL-36γ also can function as an agonist of NF-kappa B activation through the orphan IL-1- receptor-related protein 2. Recombinant murine IL-36γ is synthesized as a 17.3kDa, 152 amino acid (a.a.) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site. Murine to human, IL-36γ shares 53% a.a. identity. Within the family, IL-36γ shares about 25% ~ 55% a.a. sequence identity with IL-1RA, IL-1β, IL-36RA, IL-36α, IL- 37, IL-36β and IL-1F10.
